Q-omics provides the consensus-scored SMOX profile across patient tissues and cancer cell-line models. SMOX expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SMOX is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, SMOX RNA expression shows 16,925 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, COAD, and ACC as cancer lineages where SMOX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMOX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMOX survival associations across molecular data types. SMOX RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMOX RNA expression–survival associations across cancer types. High SMOX expression shows unfavorable associations in LUAD, LIHC, COAD and LUSC, but favorable associations in UVM and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SMOX RNA expression.
This table summarizes SMOX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SMOX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMOX shows higher tumor expression in COAD, HNSC, KIRC, LIHC, LUSC and LUAD. The COAD box plot shows higher SMOX RNA expression in tumor versus normal tissue (log2 FC = +2.601, t-test p < 0.001).
This table shows molecular features associated with SMOX in patient tissues and cancer cell lines. In patient samples, SMOX shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMOX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
